Altana Omnaris Adrenal Function Assessment Was “Not Ideal,” FDA Says
Executive Summary
Study design deficiencies impeded Altana's attempt to distinguish Omnaris (ciclesonide) from other nasal corticosteroids as having less potential to suppress the cortisol system and adrenal function
You may also be interested in...
Omnaris Launch Delayed While Altana Sniffs Out Marketing Partner
Altana will need to secure a marketing agreement with an outside partner before introducing its newly approved allergic rhinitis treatment Omnaris (ciclesonide nasal spray), the company said
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.